CL2009001010A1 - Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea. - Google Patents

Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.

Info

Publication number
CL2009001010A1
CL2009001010A1 CL2009001010A CL2009001010A CL2009001010A1 CL 2009001010 A1 CL2009001010 A1 CL 2009001010A1 CL 2009001010 A CL2009001010 A CL 2009001010A CL 2009001010 A CL2009001010 A CL 2009001010A CL 2009001010 A1 CL2009001010 A1 CL 2009001010A1
Authority
CL
Chile
Prior art keywords
composition
treatment
progesterone
estrogen
endiometrosis
Prior art date
Application number
CL2009001010A
Other languages
English (en)
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2009001010A1 publication Critical patent/CL2009001010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Método de tratamiento de una condición dependiente de estrógenos, que comprende administrarle a una mujer una composición que comprende un antagonista de progesterona por un período que comienza durante la fase lutea de dicho ciclo menstrual, en donde el endometrio de dicha mujer no es engrosado durante dicho período.
CL2009001010A 2008-04-28 2009-04-28 Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea. CL2009001010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CL2009001010A1 true CL2009001010A1 (es) 2009-06-19

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001010A CL2009001010A1 (es) 2008-04-28 2009-04-28 Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.

Country Status (24)

Country Link
US (2) US8426394B2 (es)
EP (1) EP2293797B1 (es)
JP (1) JP5791499B2 (es)
KR (2) KR20130059442A (es)
CN (2) CN102014923A (es)
AR (1) AR071516A1 (es)
AU (1) AU2009241355B2 (es)
BR (1) BRPI0911563A2 (es)
CA (1) CA2722753C (es)
CL (1) CL2009001010A1 (es)
DK (1) DK2293797T3 (es)
EA (3) EA201990835A3 (es)
ES (1) ES2561810T3 (es)
IL (1) IL208844A0 (es)
ME (1) ME01123B (es)
MX (1) MX2010011272A (es)
MY (1) MY161059A (es)
NI (1) NI201000183A (es)
NZ (1) NZ589533A (es)
SG (1) SG10201408483QA (es)
TW (1) TWI477276B (es)
UA (1) UA102849C2 (es)
WO (1) WO2009134718A1 (es)
ZA (1) ZA201007529B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
ES2701400T3 (es) * 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2914268B1 (en) * 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
NZ276105A (en) * 1993-11-16 2001-04-27 Schering Ag Use of nitric oxide synthase substrate and/or nitric oxide donor optionally with other compounds to prevent uterine contraction or a nitric oxide inhibitor to stimulate uterine contraction
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
AU714959B2 (en) * 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DK0900234T3 (da) 1996-05-01 2000-11-06 Us Gov Health & Human Serv 21-substituerede progesteronderivater anvendt som nye antigestagener
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
CA2403756C (en) * 2000-03-17 2010-02-09 Hyun K. Kim Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (es) * 2000-03-28 2003-09-13 Dabur Res Foundation
BR0110054A (pt) 2000-04-03 2003-01-28 Astenjohnson Inc Componentes de laço previamente ondulados
BR0114665A (pt) * 2000-10-18 2004-01-13 Schering Ag Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
DE60228583D1 (de) 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
EP1768625B1 (en) * 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
JP2010516686A (ja) * 2007-01-17 2010-05-20 レプロス セラピューティクス インコーポレイティド ステロイド誘導体の安定性向上のための方法
JP5379121B2 (ja) 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
PT2148681E (pt) 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル

Also Published As

Publication number Publication date
US20110046098A1 (en) 2011-02-24
AU2009241355A1 (en) 2009-11-05
EA201401347A1 (ru) 2015-07-30
EA201990835A2 (ru) 2019-08-30
US20130289008A1 (en) 2013-10-31
JP2011518845A (ja) 2011-06-30
CN102014923A (zh) 2011-04-13
BRPI0911563A2 (pt) 2016-07-12
IL208844A0 (en) 2011-01-31
MX2010011272A (es) 2010-12-21
US8735381B2 (en) 2014-05-27
CN105616427A (zh) 2016-06-01
WO2009134718A8 (en) 2010-09-23
KR20130059442A (ko) 2013-06-05
ZA201007529B (en) 2011-07-27
TWI477276B (zh) 2015-03-21
MY161059A (en) 2017-04-14
TW200950786A (en) 2009-12-16
WO2009134718A1 (en) 2009-11-05
NZ589533A (en) 2012-06-29
EP2293797A1 (en) 2011-03-16
ES2561810T3 (es) 2016-03-01
CA2722753A1 (en) 2009-11-05
JP5791499B2 (ja) 2015-10-07
SG10201408483QA (en) 2015-02-27
EA032646B1 (ru) 2019-06-28
EA201990835A3 (ru) 2019-12-30
CA2722753C (en) 2018-07-03
AR071516A1 (es) 2010-06-23
DK2293797T3 (en) 2016-01-11
EP2293797B1 (en) 2015-11-11
EA201071249A1 (ru) 2011-08-30
NI201000183A (es) 2012-06-06
UA102849C2 (ru) 2013-08-27
KR20110014162A (ko) 2011-02-10
AU2009241355B2 (en) 2013-11-14
ME01123B (me) 2013-03-20
US8426394B2 (en) 2013-04-23

Similar Documents

Publication Publication Date Title
CL2009001010A1 (es) Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.
MD3518933T2 (ro) Metode de tratare a fibromului uterin și endometriozei
AR048722A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
PE20081738A1 (es) Progesterona para el tratamiento o prevencion del parto prematuro espontaneo
BRPI0404688B8 (pt) composição para tratamento vaginal, uso da mesma, óvulo de tratamento, creme de tratamento, tampão vaginal para tratamento, e, forro de calcinha para tratamento
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
MX363697B (es) Formulaciones orales de derivados de pirrolidina.
BR112015008689A2 (pt) método para fabricar um supositório, kit, supositório e aparelho para inserir um supositório
MA38994A1 (fr) Compositions d'acides gras à libération contrôlée pour la reconstruction corporelle et le modelage corporel
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
CN204134027U (zh) 一种药物缓释妇科内裤
CN203710474U (zh) 一种医用自我注射装置
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
CN103860981A (zh) 一种用于月经不调的中药
CN204501241U (zh) 医用弹力袜助穿装置
CN204581290U (zh) 一种用于快速测量肌腱直径的装置
Stokoz et al. THE EFFECTIVENESS OF ACUPUNCTURE IN WOMEN WITH INSUFFICIENT LUTEAL PHASE OF THE MENSTRUAL CYCLE DURING PREGNANCY
CN204500668U (zh) 骨筋膜室组织内压测定装置
Tutanc Levothyroxine-sodium
AR109759A1 (es) Métodos para tratar fibroides uterinos y endometriosis y uso
CN201356599Y (zh) 挂钩保洁式止血带
CN102755624B (zh) 治疗宫寒的外用药物及其制备方法
PE20070769A1 (es) Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional
Bickers Ethinyl estradiol in the treatment of metrorrhagia